PT800578E - Sequencias do anticorpo 3h1 anti-idiotipico monoclonal recombinante associado ao antigenio carcioembrionario humano - Google Patents

Sequencias do anticorpo 3h1 anti-idiotipico monoclonal recombinante associado ao antigenio carcioembrionario humano

Info

Publication number
PT800578E
PT800578E PT95944450T PT95944450T PT800578E PT 800578 E PT800578 E PT 800578E PT 95944450 T PT95944450 T PT 95944450T PT 95944450 T PT95944450 T PT 95944450T PT 800578 E PT800578 E PT 800578E
Authority
PT
Portugal
Prior art keywords
antigen
carcioembrianary
idiotipic
sequences
human
Prior art date
Application number
PT95944450T
Other languages
English (en)
Inventor
Malaya Chatterjee
Sunil K Chatterjee
Kenneth A Foon
Heinz Kohler
Original Assignee
Univ Kentucky
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kentucky filed Critical Univ Kentucky
Publication of PT800578E publication Critical patent/PT800578E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PT95944450T 1994-12-28 1995-12-28 Sequencias do anticorpo 3h1 anti-idiotipico monoclonal recombinante associado ao antigenio carcioembrionario humano PT800578E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36548494A 1994-12-28 1994-12-28

Publications (1)

Publication Number Publication Date
PT800578E true PT800578E (pt) 2003-09-30

Family

ID=23439088

Family Applications (2)

Application Number Title Priority Date Filing Date
PT95944582T PT796280E (pt) 1994-12-28 1995-12-28 Anticorpo monoclonal 3h1 anti-idiotipico dos murinos
PT95944450T PT800578E (pt) 1994-12-28 1995-12-28 Sequencias do anticorpo 3h1 anti-idiotipico monoclonal recombinante associado ao antigenio carcioembrionario humano

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT95944582T PT796280E (pt) 1994-12-28 1995-12-28 Anticorpo monoclonal 3h1 anti-idiotipico dos murinos

Country Status (12)

Country Link
US (3) US5977315A (pt)
EP (3) EP1298144A3 (pt)
JP (2) JPH10511846A (pt)
AT (2) ATE237687T1 (pt)
AU (2) AU704829B2 (pt)
CA (2) CA2209172C (pt)
DE (2) DE69530415T2 (pt)
DK (2) DK0800578T3 (pt)
ES (2) ES2196098T3 (pt)
MX (2) MX9704898A (pt)
PT (2) PT796280E (pt)
WO (2) WO1996020219A2 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996020219A2 (en) * 1994-12-28 1996-07-04 University Of Kentucky Murine monoclonal anti-idiotype antibody 3h1
US6235280B1 (en) * 1996-04-12 2001-05-22 Malaya Chatterjee Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1
US20020041872A1 (en) 1996-04-12 2002-04-11 Malaya Chatterjee Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1
ATE233102T1 (de) * 1996-05-15 2003-03-15 Altarex Inc Verfahren und zusammensetzung zur umgestaltung multi-epitopischer antigene um die immunantwort einzuleiten
US7318921B2 (en) * 1996-05-15 2008-01-15 Altarex Medical Corp. Therapeutic compositions that alter the immune response
US20080220012A1 (en) * 1996-05-15 2008-09-11 Ragupathy Madiyalakan Therapeutic Compositions that alter the immune response
US20020098190A1 (en) * 1997-06-13 2002-07-25 Malaya Chatterjee Compositions and methods for treating tumors bearing HMFG and CEA antigens
JP2001509369A (ja) * 1997-07-08 2001-07-24 ノボファーム バイオテック インコーポレイテッド ガン細胞を特異的に検出する４ｂ５と命名される抗原結合フラグメント、フラグメントをコードするヌクレオチド、ならびにガンの予防および検出のためのそれらの使用
US7569674B2 (en) 1998-05-04 2009-08-04 Innexus Biotechnology International Limited Autophilic antibodies
US6355244B1 (en) 1997-11-17 2002-03-12 University Of Kentucky Research Foundation Methods and compositions for the treatment of psoriasis
AT409086B (de) * 1999-11-16 2002-05-27 Igeneon Krebs Immuntherapie Neue verwendung von antikörpern als impfstoffe
US6774209B1 (en) * 2000-04-03 2004-08-10 Dyax Corp. Binding peptides for carcinoembryonic antigen (CEA)
US8101200B2 (en) 2000-04-13 2012-01-24 Angiotech Biocoatings, Inc. Targeted therapeutic agent release devices and methods of making and using the same
US20020139628A1 (en) * 2001-03-30 2002-10-03 Wen-Chen Chang Retractable handle assembly
US8029803B2 (en) * 2002-06-20 2011-10-04 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US8025873B2 (en) * 2002-06-20 2011-09-27 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
AT500650B1 (de) * 2003-04-17 2009-11-15 Altropus Gmbh Immunogener rekombinanter antikörper
US8007805B2 (en) * 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens
WO2006017481A2 (en) * 2004-08-05 2006-02-16 R & D Green Materials, Llc Low temperature molding process for making solid biodegradable articles
AU2005309434A1 (en) * 2004-11-24 2006-06-01 Board Of Regents, The University Of Texas System Method for identifying and designing immunogenic peptides
US20090238822A1 (en) * 2005-10-13 2009-09-24 Virexx Medical Corp. Chimeric Hepatitis C Virus Antigens For Eliciting an Immune Response
US8603466B2 (en) * 2006-03-29 2013-12-10 King's College London Agonist antibodies against TSHR
TWI434855B (zh) * 2006-11-21 2014-04-21 Hoffmann La Roche 結合物及其在免疫分析中作為參考標準之用途
MX2010004910A (es) 2007-11-08 2010-05-14 Neogenix Oncology Inc Anticuerpos monoclonales recombinantes y antigenos correspondientes para canceres colonico y pancreatico.
US8093018B2 (en) * 2008-05-20 2012-01-10 Otsuka Pharmaceutical Co., Ltd. Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same
RU2571489C2 (ru) 2009-10-26 2015-12-20 Нестек С.А. Способы выявления препаратов и аутоантител против tnf
BR112013009376A2 (pt) 2010-10-18 2016-07-26 Nestec Sa métodos para determinar isótipos de anticorpos antifármacos
MX343324B (es) 2011-07-06 2016-11-01 Nestec Sa Ensayos para detectar auto anticuerpos neutralizadores de la terapia biologica con tnf alpha.
MA40094B1 (fr) * 2014-08-06 2022-05-31 Univ Miami Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
BR112017011545A2 (pt) 2014-12-05 2018-03-13 Nestec Sa ensaio de desvio de mobilidade homogênea indireto para a detecção de produtos biológicos nas amostras do paciente
MX2020009975A (es) 2018-03-28 2020-10-12 Bristol Myers Squibb Co Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso.

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3996345A (en) * 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
JPS54140710A (en) * 1978-03-10 1979-11-01 Mitsui Toatsu Chem Inc Anti-tumor substance and its preparation
JPS56145222A (en) * 1980-04-28 1981-11-11 Toshiyuki Hamaoka Improved antibody and its preparation
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4436728A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US5053224A (en) 1983-11-07 1991-10-01 Hilary Koprowski Induction of antibody response to solid tumors with anti-idiotype antibodies
ATE45285T1 (de) 1983-11-07 1989-08-15 Wistar Inst Durch antiidiotype antikoerper induzierte immune antwort zu tumoren und viren.
US5106738A (en) 1984-01-31 1992-04-21 Akzo Nv Tumor specific monoclonal antibodies
US5180814A (en) 1984-01-31 1993-01-19 Akzo N.V. Tumor specific monoclonal antibodies
US4828991A (en) 1984-01-31 1989-05-09 Akzo N.V. Tumor specific monoclonal antibodies
US5171568A (en) 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
US4722840A (en) 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
US5160723A (en) 1985-04-19 1992-11-03 Sloan-Kettering Institute For Cancer Research Method of imaging colorectal carcinoma lesion and composition for use therein
GB2202017A (en) * 1987-03-07 1988-09-14 Alvan Michael Judson Anti-lock electric braking
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
JP2517343B2 (ja) * 1988-01-26 1996-07-24 富士写真フイルム株式会社 熱現像感光材料
JPH01207920A (ja) 1988-02-16 1989-08-21 Oki Electric Ind Co Ltd ＩｎＰ半導体薄膜の製造方法
GB8812137D0 (en) 1988-05-23 1988-06-29 Imp Cancer Res Tech Antibodies
US5183756A (en) * 1988-08-19 1993-02-02 The United States Of America As Represented By The Department Of Health And Human Services Monoclonal antibody (D612) having selective reactivity for gastrointestinal caricinomas and method for employing the same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5407684A (en) 1988-12-30 1995-04-18 Virginia Commonwealth University Use of DHEA as a medicinal
US5077284A (en) * 1988-12-30 1991-12-31 Loria Roger M Use of dehydroepiandrosterone to improve immune response
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5244801A (en) 1989-12-28 1993-09-14 Martin Tobi Process for producing monoclonal antibodies which specifically bind to benign colonic adenomatous polyps of human origin and hybridomas and monoclonal antibodies produced by said process
ATE149841T1 (de) * 1990-01-26 1997-03-15 Immunomedics Inc Impfstoffe gegen krebs und infektionskrankheiten
US5200316A (en) 1990-02-15 1993-04-06 Miles Inc. Immunoassay methods using noncross reactive cea gene family members antibodies
AU660278B2 (en) 1990-05-10 1995-06-22 Dana-Farber Cancer Institute Enhancing the association of exogenous peptides with class 1 MHC molecules on immune system cells
US5608039A (en) * 1990-10-12 1997-03-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Single chain B3 antibody fusion proteins and their uses
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
WO1993006233A1 (en) 1991-09-19 1993-04-01 Manson Lionel A Tumor immunotherapy utilizing a method of overcoming the resistance of a progressively growing tumor
US5227471A (en) * 1992-01-30 1993-07-13 Eastern Virginia Medical School Of The Medical College Of Hampton Roads Monoclonal antibody PD41 that binds to a prostate mucin antigen that is expressed in human prostatic carcinoma
JPH08502954A (ja) 1992-08-31 1996-04-02 ジェナー テクノロジーズ 抗−イディオタイプ抗体を用いた抗腫瘍ｔ細胞応答の刺激
WO1996020219A2 (en) * 1994-12-28 1996-07-04 University Of Kentucky Murine monoclonal anti-idiotype antibody 3h1

Also Published As

Publication number Publication date
ES2196098T3 (es) 2003-12-16
WO1996020219A3 (en) 1996-09-06
MX9704897A (es) 1998-06-28
EP1298144A2 (en) 2003-04-02
WO1996020277A2 (en) 1996-07-04
EP0800578B1 (en) 2003-04-16
CA2209172C (en) 2007-04-10
JPH10511846A (ja) 1998-11-17
EP1298144A3 (en) 2006-05-31
AU717779C (en) 2002-12-05
US5977315A (en) 1999-11-02
AU717779B2 (en) 2000-03-30
DK0800578T3 (da) 2003-08-11
US7090842B1 (en) 2006-08-15
AU4692796A (en) 1996-07-19
EP0796280A2 (en) 1997-09-24
ATE235514T1 (de) 2003-04-15
EP0796280B1 (en) 2003-03-26
DE69530107D1 (de) 2003-04-30
DE69530415D1 (de) 2003-05-22
JPH11500607A (ja) 1999-01-19
DE69530415T2 (de) 2004-02-12
EP0800578A2 (en) 1997-10-15
AU4649896A (en) 1996-07-19
CA2209360A1 (en) 1996-07-04
DE69530107T2 (de) 2003-10-16
PT796280E (pt) 2003-08-29
DK0796280T3 (da) 2003-04-22
WO1996020219A2 (en) 1996-07-04
ATE237687T1 (de) 2003-05-15
ES2197217T3 (es) 2004-01-01
MX9704898A (es) 1998-06-28
CA2209172A1 (en) 1996-07-04
WO1996020277A3 (en) 1996-09-06
AU704829B2 (en) 1999-05-06
US20010047083A1 (en) 2001-11-29
CA2209360C (en) 2010-07-06

Similar Documents

Publication Publication Date Title
PT800578E (pt) Sequencias do anticorpo 3h1 anti-idiotipico monoclonal recombinante associado ao antigenio carcioembrionario humano
DE3574730D1 (de) Monoklonaler antikoerper gegen ein humanes tumor-karzinom-assoziiertes antigen.
ATE303160T1 (de) Impfstoff gegen prostatakrebs
DE69635843D1 (de) Monoklonaler anti-idiotypischer antikörper 11d10 aus der maus und methoden zu dessen verwendung
DE3783277T2 (de) Monoklonaler antikoerper gegen humanes lungenkarzinom.
EP0597829A4 (en) NEW MONOCLONAL ANTIBODY DRESSES AGAINST A NEW ANTIGEN ASSOCIATED WITH HUMAN TUMORS.
ATE272113T1 (de) Melanoma-assoziierte antigene, epitope davon und impstoffe gegen melanoma
OA08485A (fr) Monoclonal antibodies and antigen for human non-small cell lung carcinoma and certain other human carcinomas.
DE3586216T2 (de) Brusttumorassoziiertes antigen und monoklonale antikoerper dazu.
NZ228837A (en) Tumour associated antigen and the monoclonal antibody reactive with it useful in diagnosing and treating cancer
ES2059418T3 (es) Antigeno asociado a carcinoma humano y anticuerpo asociado al antigeno.
DE3485712D1 (de) Monoklonale antikoerper gegen menschliche nierenkrebsantigene und verfahren.
EP0215131A4 (en) ANTIGEN E87Ag OF PSEUDOMONAS AERUGINOSE, MONOCLONAL ANTIBODIES AGAINST THIS ANTIGEN AND HYBRIDOMA.
ZA884777B (en) Antigen recognized by mca 16 88
FI924576A0 (fi) Ctaa 28a32, antigen identiefierad av mca 28a32
MX9202642A (es) Anticuerpos monoclonales y antigeno para melanoma humano.
DK182188A (da) Humant tumorassocieret antigen
IL127249A0 (en) Human monoclonal antibodies to the hepatitis b surface antigen